期刊文献+

达格列净治疗2型糖尿病肾病患者的临床疗效观察 被引量:14

Observation of the Clinical Effect of Dapagliflozin on Patients with Type 2 Diabetic Nephropathy
下载PDF
导出
摘要 目的:研究SGLT-2抑制剂达格列净治疗2型糖尿病肾病患者的临床疗效。方法:挑选60例血糖控制欠佳的2型糖尿病肾病患者,随机分为两组,加用达格列净10mg/d作为观察组,加用安慰剂1片/d作为对照组,共治疗12周,记录治疗前后所有被检患者的一般资料及临床指标,并进行统计分析。结果:对照组与观察组干预前各项基线指标相近(P>0.05)。对照组治疗前后各指标均无明显改变(P>0.05);观察组治疗后体重、体质指数、空腹血糖、糖化血红蛋白、血肌酐、24h尿蛋白定量、血尿酸均较治疗前下降,空腹C肽及餐后2h C肽均较治疗前升高(P<0.05),而治疗前后TG、TC、HDL-C和LDL-C均无明显改变(P>0.05);干预后观察组患者的体重、体质指数、空腹血糖、糖化血红蛋白、血肌酐、24h尿蛋白定量、血尿酸水平均较对照组下降,空腹C肽较对照组上升(P<0.05),两组干预后TG、TC、HDL-C、LDL-C及餐后2h C肽差异无统计学意义(P>0.05)。结论:达格列净可以有效控制2型糖尿病肾病患者的血糖,改善其胰岛功能,并降低其尿蛋白、血肌酐及尿酸,从而保护肾功能。 Objective:In this study, we investigated the clinical curative effect of observation of dapagliflozin on patients with type 2 diabetic nephropathy.Methods:60 patients with type 2 diabetic nephropathy having not reached the glycemic targets were divided into two groups:the observation group was received with dapagliflozin 10 mg/d and the control group was received with placebo with a course of 12 weeks. General informations and clinical indicators of all patients before and after treatment were recorded, all results were statistically analyzed.Results:There were no significant changes in baseline charateristics between the two groups(P>0.05).The levels of body weight,BMI,FBG,HbA1 c,Scr,24-hour urinary protein quantification and UA were all decreased,fasting C-peptide and 2-hour postprandial C-peptide were all increased(P<0.05),while there were no significant changes in TG,TC,HDL-C and LDL-C after treatment in the observation group(P>0.05).The levels of body weight,BMI,FBG,HbA1 c,Scr and 24 hours urinary protein quantitative,UA were decreased,fasting C-peptide were increased(P<0.05), while there were no significant changes in TG,TC,HDL-C,LDL-C and 2-hour postprandial C-peptide(P>0.05) after treatment in the observation group compared with the control group.Conclusion:Dapagliflozin can effectively control the blood sugar of patients with type 2 diabetic nephropathy,improve the function of pancreatic islets,and reduce their urinary protein serum creatinine and uric acid,thereby protecting renal function.
作者 张倩倩 叶启宝 陈丽 马维青 ZHANG Qianqian;YE Qibao;CHEN Li(Department of Endocrinology,Hefei First People’s Hospital,Hefei City,Anhui Province 230000)
出处 《医学理论与实践》 2019年第22期3591-3593,共3页 The Journal of Medical Theory and Practice
关键词 2型糖尿病 糖尿病肾病 达格列净 胰岛功能 肾功能 Type 2 diabetes mellitus Diabetic nephropathy Dapagliflozin Islet function Renal function
  • 相关文献

参考文献3

二级参考文献44

  • 1Nam Han Cho (chair) ,David Whiting (deputy chair). IDF DIA- BETES ATLAS Seventh Edition 2015 [ EB/OL]. (2015-12-01) [ 2016-01-10 ]. http ://www. diabetesatlas, org/.
  • 2Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death[J]. N Engl J Meal,2011,364(9) :829-841.
  • 3Buse JB, Ginaberg HN, Bakris GL,et al. Primary prevention of car- diovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association[J]. Diabetes Care,2007,30( 1 ) :162-172.
  • 4Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study [ J ]. Circulation,2007,115 (12) : 1544-1550.
  • 5Haffner SM, Lehto S, R6nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction[ J]. N Engl J Med, 1998,339 (4) :229-234.
  • 6Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[ J]. Diabetes Obes Metab,2014,16(7) :628-635.
  • 7Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorpfion in the early proximal tubule[J]. J Am Soc Nephrol, 2011,22( 1 ) :104-112.
  • 8Abdul-Ghani MA, DeFronzo RA. Inhibition of re~al glucose reab- sorption:a novel strategy for achieving glucose control in type 2 diabetes mellitus [ J ]. Endocr Pract,2008,14 (6) :782-790.
  • 9Liu JJ, Lee T, DeFrenzo RA. Why Do SGLT2 inhibitors inhibit only 30%-50% of renal glucose reabsorption in humans? [ J]. Diabetes,2012,61 (9) :2199-2204.
  • 10Ferrannini E, Ramos S J, Salsali A,et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial[ J ]. Diabetes Care ,2010,33 (10) :2217-2224.

共引文献1175

同被引文献129

引证文献14

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部